Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart J Pocock

Showing results (151-160 of 349) with videos related to

Pageof 35
Sort By:
European Journal of Heart Failure|January 24, 2014
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-PreservedJennifer K Rogers, Stuart J Pocock, John J V McMurray, et al.
European Heart Journal|October 13, 2005
Predictors of mortality and morbidity in patients with chronic heart failureStuart J Pocock, Duolao Wang, Marc A Pfeffer, et al.
European Heart Journal|August 26, 2022
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programmeFaiez Zannad, João Pedro Ferreira, Javed Butler, et al.
European Heart Journal|May 19, 2016
Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-studyChristoph K Naber, Philip Urban, Paul J Ong, et al.
Journal of the American College of Cardiology|October 7, 2017
Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMIGennaro Giustino, Roxana Mehran, George D Dangas, et al.
European Journal of Heart Failure|April 16, 2023
Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trialAbhinav Sharma, João Pedro Ferreira, Faiez Zannad, et al.
European Journal of Heart Failure|February 16, 2019
Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trialJoão Pedro Ferreira, Paula Abreu, John J V McMurray, et al.
Heart (British Cardiac Society)|September 21, 2011
Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trialsPeter Damman, Tim Clayton, Lars Wallentin, et al.
European Journal of Heart Failure|February 3, 2016
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF studyKen Lee Chin, Timothy J Collier, Bertram Pitt, et al.
The New England Journal of Medicine|April 5, 2016
Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial FibrillationKarl-Heinz Kuck, Josep Brugada, Alexander Fürnkranz, et al.
Pageof 35

Showing results (151-160 of 349) with videos related to

Sort By:
Pageof 35
European Journal of Heart Failure|January 24, 2014
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-PreservedJennifer K Rogers, Stuart J Pocock, John J V McMurray, et al.
European Heart Journal|October 13, 2005
Predictors of mortality and morbidity in patients with chronic heart failureStuart J Pocock, Duolao Wang, Marc A Pfeffer, et al.
European Heart Journal|August 26, 2022
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programmeFaiez Zannad, João Pedro Ferreira, Javed Butler, et al.
European Heart Journal|May 19, 2016
Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-studyChristoph K Naber, Philip Urban, Paul J Ong, et al.
Journal of the American College of Cardiology|October 7, 2017
Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMIGennaro Giustino, Roxana Mehran, George D Dangas, et al.
European Journal of Heart Failure|April 16, 2023
Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trialAbhinav Sharma, João Pedro Ferreira, Faiez Zannad, et al.
European Journal of Heart Failure|February 16, 2019
Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trialJoão Pedro Ferreira, Paula Abreu, John J V McMurray, et al.
Heart (British Cardiac Society)|September 21, 2011
Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trialsPeter Damman, Tim Clayton, Lars Wallentin, et al.
European Journal of Heart Failure|February 3, 2016
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF studyKen Lee Chin, Timothy J Collier, Bertram Pitt, et al.
The New England Journal of Medicine|April 5, 2016
Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial FibrillationKarl-Heinz Kuck, Josep Brugada, Alexander Fürnkranz, et al.
Pageof 35